Article and Video CATEGORIES

Cancer Journey

Search By

Basic Principles of Managing Locally Advanced NSCLC
Author
GRACE Videos and Articles
 
Note: This is an older video and may contain outdated information.
 
GRACE Cancer Video Library - Lung

GCVL_LU-E02_Locally_Advanced_NSCLC_Management

 

Dr. West reviews basic principles of treating locally advanced lung cancer, including the need to treat both local disease and possible distant disease, and the need to balance efficacy with toxicity.

[powerpress]

Download Transcript

[ratingwidget post_id=0]

Please feel free to offer comments and raise questions in our Discussion Forums.

 

Transcript

About a third of the patients who are diagnosed with lung cancer that is non-small cell lung cancer, the most common type, present with stage 3, or locally advanced disease, and this is defined by an extent of tumor that is beyond what can be surgically removed, and/or lymph node involvement that is extensive enough that it is not felt at all likely that surgery, as the primary modality, at least likely on its own, will be enough to be curative. However, if patients don’t have distant disease — don’t have evidence of disease that has spread to common areas like the bones, the other parts of the lungs, the brain, the liver, etc., it is often possible to treat with curative intent. It can be challenging, and it almost always requires a multi-modality approach; that means that we need to give two, or sometimes three different main strategies of fighting the cancer. Those leading strategies are systemic treatment, such as chemotherapy, local therapy, such as radiation, or the local therapy of surgery — cutting it out. And, for many patients with stage 3, or locally advanced lung cancer, we need to combine multiple different modalities. This almost always involves a systemic therapy, like chemotherapy, with radiation and/or surgery.

GCVL_LU-E02_Locally_Advanced_NSCLC_Management 1a ML.001

So, the idea is that there are two main threats; the local threat posed by a tumor that’s growing aggressively in the chest, and a distant threat posed by disease that could be escaping in the bloodstream to other parts of the body, and that is reflected primarily by the nodal disease — the lymph node’s involved. So, we worry more about whole body threat of disease when there are multiple lymph nodes involved in several stations in the middle of the chest. On the other hand, we might be much more concerned about local control if the lymph nodes are not as much of an issue, but the cancer is growing quite invasive and larger. But, we will almost always want to combine a systemic therapy with a local therapy, and sometimes give even two local therapies, like giving chemotherapy and radiation, followed by surgery. It’s certainly an aggressive approach.

GCVL_LU-E02_Locally_Advanced_NSCLC_Management 1a ML.002

This is the second issue to really cover here, and that is that local therapy, combined with systemic therapy, is the most aggressive approach that we can offer, but it really involves threading a needle — trying to balance between the maximum efficacy we can deliver against the cancer, but having it be tolerable enough for a patient to get through it safely, without too much of a threat to their survival, or long-term side effects from the treatment. But this is really pushing against the limit, pushing into the red zone for patients, for getting through all of it.

What we typically will give is concurrent chemo and radiation and, that way, by giving chemotherapy with the radiation, it helps the radiation be more effective where it’s directed, and the chemotherapy can also work in other parts of the body. But by doing that, it’s a more challenging approach, and some patients, perhaps as many as 5% or 6%, even in well done clinical trials, patients being watched carefully, can have life-threatening complications. So, it really involves attentive care for patients, and close follow up. But this is the best way of achieving long-term survival for patients with locally advanced, non-small cell lung cancer, provided they’re well enough to tolerate it.

Next Previous link

Previous PostNext Post

Related Content

Image
Clinical Trials Storytelling 2025
Article
GRACE is pleased to introduce three amazing individuals participating in the 2024-25 GRACE Clinical Trials Experiences Storytelling Program
Article
Advance directives are a powerful way to take control of healthcare choices. These documents allow you to outline preferences for medical care and specify end-of-life wishes. These documents can also be a way to appoint loved ones who you would like to help with these decisions, such as a healthcare proxy (someone to make decisions on your behalf, if you cannot). As cancer treatments can involve aggressive treatments and/or complex medical management, having advance directives ensures that your desires regarding treatment options and end-of-life care are clearly communicated. 
Image
2024-25 patient perspectives header
Article
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial.  We want to hear from you!

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Glad to help.  FYI, I just edited the link, which has the agenda and links to oncologists' bios. Plus, the link is also on our home page, https://cancergrace.org/

Hope to see...

Recent Comments

JOIN THE CONVERSATION
Hi bluesun,I don't know of…
By JanineT GRACE … on
Amivantamab and Lazertinib
By happybluesun on
Glad to help.  FYI, I just…
By JanineT GRACE … on
I was searching for this,…
By LilahStapleton on